- Home
- SNTI vs FTHM Comparison
SNTI vs FTHM Comparison
Compare SNTI & FTHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- FTHM
- Stock Information
- Founded
- SNTI 2016
- FTHM 2010
- Country
- SNTI United States
- FTHM United States
- Employees
- SNTI N/A
- FTHM N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- FTHM Real Estate
- Sector
- SNTI Health Care
- FTHM Finance
- Exchange
- SNTI Nasdaq
- FTHM Nasdaq
- Market Cap
- SNTI 39.6M
- FTHM 38.3M
- IPO Year
- SNTI N/A
- FTHM 2020
- Fundamental
- Price
- SNTI $1.37
- FTHM $2.63
- Analyst Decision
- SNTI Strong Buy
- FTHM
- Analyst Count
- SNTI 2
- FTHM 0
- Target Price
- SNTI $8.50
- FTHM N/A
- AVG Volume (30 Days)
- SNTI 120.0K
- FTHM 1.6M
- Earning Date
- SNTI 11-13-2025
- FTHM 11-06-2025
- Dividend Yield
- SNTI N/A
- FTHM N/A
- EPS Growth
- SNTI N/A
- FTHM N/A
- EPS
- SNTI N/A
- FTHM N/A
- Revenue
- SNTI N/A
- FTHM $390,032,000.00
- Revenue This Year
- SNTI N/A
- FTHM $25.22
- Revenue Next Year
- SNTI $150.00
- FTHM $16.19
- P/E Ratio
- SNTI N/A
- FTHM N/A
- Revenue Growth
- SNTI N/A
- FTHM 19.16
- 52 Week Low
- SNTI $1.26
- FTHM $0.65
- 52 Week High
- SNTI $16.94
- FTHM $3.37
- Technical
- Relative Strength Index (RSI)
- SNTI 37.01
- FTHM 64.22
- Support Level
- SNTI $1.33
- FTHM $1.80
- Resistance Level
- SNTI $1.39
- FTHM $3.09
- Average True Range (ATR)
- SNTI 0.08
- FTHM 0.39
- MACD
- SNTI 0.01
- FTHM 0.07
- Stochastic Oscillator
- SNTI 31.43
- FTHM 55.05
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.